IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors. - Wikidata - wikimedia - TriplyDB

IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors.

IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors.

http://www.wikidata.org/entity/Q35578622

about

Regulation of IL-10 and IL-12 production and function in macrophages and dendritic cells Immunosuppressive Mechanisms of Malignant Gliomas: Parallels at Non-CNS Sites The impact of the myeloid response to radiation therapy Interleukin 12: still a promising candidate for tumor immunotherapy?Immune modulation of the tumor microenvironment for enhancing cancer immunotherapy Chimeric antigen receptor therapy for cancer Identification of the genomic insertion site of Pmel-1 TCR α and β transgenes by next-generation sequencing Signal transducer and activator of transcription 3 in myeloid-derived suppressor cells: an opportunity for cancer therapy T-cell receptor gene therapy--ready to go viral?Enhancing the discovery and development of immunotherapies for cancer using quantitative and systems pharmacology: Interleukin-12 as a case study Coordinated regulation of myeloid cells by tumours The dark side of dendritic cells: development and exploitation of tolerogenic activity that favor tumor outgrowth and immune escape.Myeloid derived suppressor cells - a new therapeutic target in the treatment of cancer.Strategies to genetically engineer T cells for cancer immunotherapy.Depletion of myeloid-derived suppressor cells during interleukin-12 immunogene therapy does not confer a survival advantage in experimental malignant glioma.Immune-based antitumor effects of BRAF inhibitors rely on signaling by CD40L and IFNγ.Stromal reengineering to treat pancreas cancer The indoleamine 2,3-dioxygenase pathway controls complement-dependent enhancement of chemo-radiation therapy against murine glioblastoma.The basic principles of chimeric antigen receptor design.Adoptive cell transfer as personalized immunotherapy for human cancer.CAR-modified T-cell therapy for cancer: an updated review.Driving CAR T-cells forward DC-HIL-expressing myelomonocytic cells are critical promoters of melanoma growth.New insights into IL-12-mediated tumor suppression.Reassessing target antigens for adoptive T-cell therapy.Targeting the tumor microenvironment to enhance antitumor immune responses IFNγ producing CD8(+) T cells modified to resist major immune checkpoints induce regression of MHC class I-deficient melanomas TLR5 Ligand-Secreting T Cells Reshape the Tumor Microenvironment and Enhance Antitumor Activity.IL-12 Inhibits Lipopolysaccharide Stimulated Osteoclastogenesis in Mice.Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanoma Dendritic Cells in Irradiated Mice Trigger the Functional Plasticity and Antitumor Activity of Adoptively Transferred Tc17 Cells via IL12 Signaling Adjuvants and myeloid-derived suppressor cells: enemies or allies in therapeutic cancer vaccination.Development of individualized anti-metastasis strategies by engineering nanomedicines Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning.L-Arginine supplementation inhibits the growth of breast cancer by enhancing innate and adaptive immune responses mediated by suppression of MDSCs in vivo.Characterization of a mutated IgA2 antibody of the m(1) allotype against the epidermal growth factor receptor for the recruitment of monocytes and macrophages.Interleukin-6/STAT3 Pathway Signaling Drives an Inflammatory Phenotype in Group A Ependymoma Inhibiting systemic autophagy during interleukin 2 immunotherapy promotes long-term tumor regression.Prime-boost vaccination with SA-4-1BBL costimulatory molecule and survivin eradicates lung carcinoma in CD8+ T and NK cell dependent manner.Immunotherapy of malignant disease using chimeric antigen receptor engrafted T cells

P2860

Q26766184-F39C4742-8366-4FB9-812F-E18565A83B75 Q26798402-53EA28A8-E568-4F06-A8FB-9E95CE86BCA6 Q26851643-695273ED-6384-4853-AE6B-B393AFB8F177 Q26861559-51CBCC1D-8879-4699-87AA-6EF79EA9EEB4 Q27002646-6140F258-72B2-45E4-A28B-37FC7877D112 Q27013599-7D57CF98-5B9A-47AF-81BC-A8DEE4D747DA Q27334215-DB1D1262-F5E3-46A2-A7A2-A6D38B720271 Q28080262-0B7AD6B9-C3BF-4633-BF28-01BF69EAFB5F Q28081611-B88215CE-C1F5-42A8-A153-710F4B0EE569 Q28084489-EBE079DD-680C-4DB3-88EC-8582EEB6A781 Q28395157-815E4DCE-A12B-4383-852E-762B42C46CA9 Q30317628-B140B914-B8C3-4904-9965-7120CA1160FF Q33606107-A70D46BE-6011-4316-8145-836078E635F7 Q33655849-6E606A27-25EF-4164-A97B-4A2A8BED5202 Q33670136-F25A699A-94EE-42F4-8D9C-A1C7C8953635 Q33776925-F92A6582-12E6-4BD9-9F26-432C96A0E677 Q33827708-48866784-BF66-4EB8-8843-D7CD5D707A69 Q33929529-8CEC646C-5695-447A-B103-137C39A87E1A Q34036213-5B247D70-1AE6-4B9E-B6B8-91FD57D114D8 Q34043643-79E2677E-C90B-4321-B303-7613AB057178 Q34044213-A8F5EC0A-BAA4-47AA-8FE0-EE32C904970A Q34046505-C078D76B-4AA9-44F2-97D6-E12F186109B9 Q34353081-5E1D9B77-E660-4BC7-B746-EE1DB2371881 Q34436897-9B1603A6-22BE-4117-9E06-245387AF440A Q34789569-B07B0664-8469-42AB-AF0F-AF7E62020C5B Q35176307-A71680D0-5DAA-4DC0-8978-0392A211E53D Q35507485-4D30B683-1A91-4D30-9BB8-A487812F2A41 Q35612358-BD0C3C99-871A-4BE0-9D27-179697E50FD5 Q35612643-C2727FD7-6683-4BAE-8050-5AF58BFC43D0 Q35613148-77754CC6-13A6-40F7-B77B-0C5A5E0CECBF Q35674805-B48854A7-7C74-4DAF-8553-14BC37CA28D7 Q35886450-8EA45EB5-EA13-4170-90E7-900B7A264DEE Q35967474-708F4A92-A14E-4DCF-BADE-041E0C0C0D21 Q35986612-2ADB42FC-9D16-4504-A644-48ADC245AE41 Q36035570-371D18C3-EA28-45B4-9ECC-50BFB8A53253 Q36127055-A2FAB2EC-28D8-4EF4-9C45-2B7C0F5A3833 Q36132647-71701E86-097A-40B2-B2FC-C6656946BA23 Q36157982-1788B04D-AB0D-4928-A407-3D8F1E5B08BC Q36384615-84A15550-2E91-4D47-A8CC-F7C667D0030F Q36470354-FDBA51E8-58D5-499D-AAE1-532CE67EF7B6

P2860

IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors.

http://www.wikidata.org/entity/Q35578622

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

IL-12 triggers a programmatic ...... ved cells within mouse tumors.

@ast

IL-12 triggers a programmatic ...... ved cells within mouse tumors.

@en

type

label

IL-12 triggers a programmatic ...... ved cells within mouse tumors.

@ast

IL-12 triggers a programmatic ...... ved cells within mouse tumors.

@en

prefLabel

IL-12 triggers a programmatic ...... ved cells within mouse tumors.

@ast

IL-12 triggers a programmatic ...... ved cells within mouse tumors.

@en

P1433

Q35578622-CDABD08F-6EAB-49E6-918E-BD26583B3206

P1476

Q35578622-D1AFAC0E-3C55-41E9-A4D5-D9FFD138A7FE

P2093

Q35578622-03C3F1B9-56A5-4AAC-9857-4C9CF96DA76C

Q35578622-29F3EE0D-E950-4C07-85C5-89FC9377C885

Q35578622-29FDBC7E-DAD4-4F80-BC7A-A6F24A009F05

Q35578622-36F3A5ED-9B2A-41EA-8F21-BB5C41C76128

Q35578622-378B965F-CB07-4738-AA0B-9E3C38960BAC

Q35578622-770B94B9-948A-4F90-A5CF-AA8CBA382808

Q35578622-835E082A-033F-4FAE-AB40-A86DE735C3E3

Q35578622-9298CA51-09A4-476B-B596-3789C1CD66D3

Q35578622-948A1013-04C5-4FDA-9611-95E7D9E3F473

Q35578622-A7ACF4BF-128C-4D7D-9C09-6062C7723F4B

P2860

Q35578622-000D097B-DE68-4043-9126-35A8022D542F

Q35578622-04C18DB8-6C76-4DA2-8CF4-7DB0DADD1E5D

Q35578622-0619742D-3D37-4114-8708-1AFCDFEC8EC6

Q35578622-07104193-3840-45EA-87F4-9B9383274A94

Q35578622-12C8956D-5BA5-4A92-950A-DD565F7BE6A7

Q35578622-14B38536-8095-4986-8F46-EEEA5AA78C0B

Q35578622-1EE293F1-38B4-4F0D-94AA-71C0781094E0

Q35578622-21D51F2E-FD44-4880-822A-FD353CE89BFA

Q35578622-269F1A0D-7A96-4943-8037-62A75893334A

Q35578622-2706CC8C-7C3D-48AD-9CAE-42D286EA555B

P304

Q35578622-0C08D663-495B-4B40-967D-681D41294F94

P31

Q35578622-A91B134F-4173-4646-AEDA-5637A0E89ECC

P356

Q35578622-B9E0D40C-C308-4B08-AF85-7D91ECD04B97

P407

Q35578622-FA236738-193C-4551-ADB8-EA66A557F697

P433

Q35578622-2AE01D32-687D-4188-9129-EB89A752441C

P478

Q35578622-7FD0BE69-A21C-477E-8EB7-62D48A37B56C

P50

Q35578622-F8E4C4D9-C858-45BA-8F4D-0966C6C70144

P577

Q35578622-0BF6D95C-279D-4ADF-9201-283AA361504D

P698

Q35578622-D2BC0EFB-C272-4681-9056-5B7E289F37C0

P932

Q35578622-E60963C3-7A19-4601-AE9C-F8FFC7A006E5

P356

P1433

Journal of Clinical Investigation

P1476

IL-12 triggers a programmatic ...... ived cells within mouse tumors

@en

P2093

Anthony J Leonardi

http://www.w3.org/2001/XMLSchema#string

Dhanalakshmi Chinnasamy

http://www.w3.org/2001/XMLSchema#string

Ena Wang

http://www.w3.org/2001/XMLSchema#string

Francesco M Marincola

http://www.w3.org/2001/XMLSchema#string

Giorgio Trinchieri

http://www.w3.org/2001/XMLSchema#string

Pawel Muranski

http://www.w3.org/2001/XMLSchema#string

Richard A Morgan

http://www.w3.org/2001/XMLSchema#string

Robert N Reger

http://www.w3.org/2001/XMLSchema#string

Romina S Goldszmid

http://www.w3.org/2001/XMLSchema#string

Sid P Kerkar

http://www.w3.org/2001/XMLSchema#string

P2860

Hallmarks of Cancer: The Next Generation

Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells

CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells.

Myeloid-derived suppressor cells: linking inflammation and cancer

Inflammation and cancer

Cancer regression in patients after transfer of genetically engineered lymphocytes

Myeloid-derived suppressor cells as regulators of the immune system

Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function

Macrophages, innate immunity and cancer: balance, tolerance, and diversity

Interleukin-12 and the regulation of innate resistance and adaptive immunity

P304

4746-4757

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1172/JCI58814

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

121

http://www.w3.org/2001/XMLSchema#string

P50

Nicholas P. Restifo

P577

2011-11-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22056381

http://www.w3.org/2001/XMLSchema#string

P932

3226001

http://www.w3.org/2001/XMLSchema#string